tesamorelin (Egrifta)

Indications

• treatment of lipodystrophy in HIV-Infected patients
  • can reduce accumulation of abdominal fat but does not treat hyperlipdemia or insulin resistance

Dosage

• once a day injection

Adverse effects

• arthralgia
• abdominal pain
• swelling
• myalgia
• erythema & pruritus at the injection site
• worsening of glycemic control

Mechanism of action

• growth hormone-releasing factor

More general terms

• endocrine agent

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=16137828
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=44201342